SynthesisJornal brasileiro de nefrologia
Battle of the giants: KDIGO vs. Cochrane - who is the winner in the fight for blood pressure targets in chronic kidney disease?
Synthesis in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension (HTN) in chronic kidney disease (CKD) is often regarded as the main villain. It represents the leading cause of dialysis-dependent CKD in Brazil and the second most common worldwide, yet it is also a frequent consequence of renal disorders that induce secondary HTN. In other words, HTN in CKD is a double-edged sword-causing disease progression when primary and aggravating existing injury when secondary, through multiple pathophysiological mechanisms. The most frequently cited blood pressure targets for CKD management in the current scientific literature come from two major authorities in evidence-based recommendations: the 2024 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guidelines and the 2024 Cochrane Library systematic review and meta-analysis. This article aims to examine and compare the blood pressure targets proposed for CKD by these two leading institutions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.